期刊文献+

ICE和GDP方案治疗复发、难治性弥漫大B细胞淋巴瘤的临床观察 预览

Clinical Observation of ICE and GDP Regimens in the Treatment of Recurrent or Refractory Diffuse Large B-cell Lymphoma
在线阅读 下载PDF
分享 导出
摘要 目的观察ICE和GDP方案治疗复发、难治性弥漫大B细胞淋巴瘤(DLBCL)的临床疗效。方法选取2014年1月-2017年1月我院收治的60例复发、难治性DLBCL患者为对象,按随机数字表法均分为对照组和实验组各30例,对照组及实验组分别给予ICE、GDP方案进行治疗,比较两组治疗后的临床疗效及不良反应。结果观察组化疗后患者出现总不良反应率为60.00%,明显低于对照组的83.33%(P<0.05);两组化疗后临床疗效无明显差异。结论ICE和GDP方案治疗复发、难治性DLBCL的临床疗效相当,后者不良反应较轻,可以更好的用于老年患者及合并心脏疾病的患者,值得在临床上进一步推广。 Objective To observe the clinical efficacy of ICE and GDP regimens in the treatment of recurrent or refractory diffuse large B-cell lymphoma(DLBCL).Methods 60 cases of patients with recurrent or refractory DLBCL who were admitted to our hospital from January 2014 to January 2017 were selected for the study and were divided into control group and experimental group according to the random number table method.Control group was given ICE chemotherapy regimen,and experimental group was treated with GDP chemotherapy regimen.The clinical efficacy and adverse reactions after treatment were compared between the two groups.Results The total adverse reaction rate in observation group after chemotherapy was,which was significantly lower than that in control group(60.00%vs 83.33%)(P<0.05).There was no significant difference in clinical efficacy between the two groups after chemotherapy.Conclusion ICE and GDP regimens can have similar clinical efficacy in the treatment of recurrent or refractory DLBCL,but the latter one has less adverse reactions and can be better used in elderly patients and patients with combined heart disease,therefore the latter one is worthy of further promotion in clinical practice.
作者 邹思平 杨瑜 陈道光 吴晖 何鸿鸣 陈英 林剑扬 陈秀容 王畅 ZOU Si-ping;YANG Yu;CHEN Dao-guang(Department of Lymphoma,Teaching Hospital of Fujian Medical University,Fujian Provincial Cancer Hospital,Fuzhou 350014,Fujian Province,China)
出处 《罕少疾病杂志》 2018年第6期3-4,36共3页 Journal of Rare and Uncommon Diseases
基金 国家临床重点专科建设项目,国卫办医函[2013]544号.
关键词 ICE GDP 复发 难治性弥漫大B细胞淋巴瘤 ICE GDP Recurrent Refractory Diffuse Large B-cell Lymphoma
作者简介 邹思平,男,主治医师,主要从事恶性淋巴瘤诊治研究;通讯作者:杨瑜.
  • 相关文献

参考文献8

二级参考文献48

  • 1Christian Récher,Bertrand Coiffier,Corinne Haioun,Thierry Jo Molina,Christophe Fermé,Olivier Casasnovas,Catherine Thiéblemont,André Bosly,Guy Laurent,Franck Morschhauser,Hervé Ghesquières,Fabrice Jardin,Serge Bologna,Christophe Fruchart,Bernadette Corront,Jean Gabarre,Christophe Bonnet,Maud Janvier,Danielle Canioni,Jean-Philippe Jais,Gilles Salles,Hervé Tilly.Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial[J]. The Lancet . 2011 (9806) 被引量:2
  • 2Zelenetz Andrew D,Abramson Jeremy S,Advani Ranjana H,Andreadis C Babis,Byrd John C,Czuczman Myron S,Fayad Luis,Forero Andres,Glenn Martha J,Gockerman Jon P,Gordon Leo I,Harris Nancy Lee,Hoppe Richard T,Horwitz Steven M,Kaminski Mark S,Kim Y.NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin’s lymphomas. Journal of the National Comprehensive Cancer Network : JNCCN . 2010 被引量:3
  • 3Sabattini E,Bacci F,Sagramoso C,Pileri S A.WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica . 2010 被引量:5
  • 4Marcucci F,Mele A. Hepatitis viruses and non-Hodgkin lymphoma:epidemiology,mechanisms of tumorigenesis,and therapeutic opportunities[J]. Blood, 2011 , 117 (6) : 1792-1798. 被引量:1
  • 5Wennekes L,Ottevanger PB,Raemaekers JM,et a|. Develo- pment and measurement of guideline-based indicators for patients with non-Hodgkin's lymphoma [J]. J Clin Oncol, 2011,29(2) : 1436-1444. 被引量:1
  • 6Cheson BD,Horning SJ,Coiffier B,et al.Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas[J].J Clin Oncol,1999,17(4):1244-1253. 被引量:1
  • 7Tarella C,Gueli A,Delaini F,et al.Rate of primary refractory disease in B and T-cell non-Hodgkin's lymphomas:correlation with long-term survival[J].PLoS One,2014,9(9):e106745. 被引量:1
  • 8Thomas DA,O'Brien S,Giles FJ,et al.Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma[J].Blood,2004,104(6):1624-1630. 被引量:1
  • 9Coiftier B,Haioun C,Ketrerer N,et al.Rituximab(anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma:a multicenter phase II study[J].Blood,1998,92(6):1927-1932. 被引量:1
  • 10Lamar ZS,Fino N,Palmer J,et al.Dose-adjusted etoposide,prednisone,vincristine,cyclophosphamide,and doxorubicin(EPOCH) with or without rituximab as first-line therapy for aggressive non-Hodgkin's lymphomas[J].Clin Lymphoma Myeloma Leuk,2015,12(15):1382-1388. 被引量:1

共引文献29

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈